However, in the absence of advanced methods of evaluating methylation status or nucleosomal structure or addition of DNMT3A to the panel (43, 48), the provenance of the TP53 alteration cannot definitively be ascribed to metastatic tumor-derived DNA. The gene discussed is TP53; the disease is metastatic neoplasm.